Cite
HARVARD Citation
Bahlis, N. et al. (2022). Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial. Leukemia & lymphoma. 63 (6), pp. 1407-1417. [Online].